Gene Therapy for Duchenne Muscular Dystrophy

Introduction to Duchenne Muscular Dystrophy (DMD)

• DMD is an X-linked muscle-wasting disease affecting 1 in 5000 males.
• Affected individuals typically become wheelchair-bound by the age of twelve and often succumb in their third decade due to respiratory and cardiac complications.
• The disease arises from mutations in the DMD gene, which codes for dystrophin, a structural protein essential for maintaining muscle fiber integrity and protection against contraction-induced damage.
• The absence of dystrophin compromises muscle fiber stability and function, leading to muscle degeneration. Currently, there’s no effective treatment to halt muscle deterioration in DMD patients.

Gene Therapy as a Promising Approach

• A potential treatment for DMD is gene transfer to restore dystrophin expression using a safe, non-pathogenic viral vector known as the adeno-associated viral (AAV) vector.
• Microdystrophin gene transfer using AAV vectors has shown significant therapeutic success in large animal models of DMD.
• However, translating this therapy from research to clinical application still requires several optimization steps.

Historical Perspectives on DMD

• Muscular dystrophy was identified as a primary muscle disease in the 19th century.
• DMD, a subtype of muscular dystrophy, affects 1 in 5000 male births.
• The disease was initially described by Edward Meryon and later characterized by Guillaume B.A. Duchenne de Boulogne.
• The gene associated with DMD was discovered through the application of positional cloning, and its protein product was named dystrophin.

Dystrophin and its Role

• The DMD gene, one of the largest protein-coding genes in the human genome, spans over 2.6 million base pairs with 79 exons coding for various dystrophin protein isoforms.
• Dystrophin is a cytoplasmic sarcolemmal protein that connects the extracellular matrix (ECM) and cortical cytoskeleton.
• The protein plays a structural role, allowing force transmission from the cell’s internal contractile elements to the ECM while maintaining muscle fiber integrity.

Becker Muscular Dystrophy (BMD)

• BMD is a milder form of dystrophinopathy compared to DMD.
• Like DMD, BMD arises from mutations in the same X-linked gene. However, BMD’s onset can be as late as 30 or 40 years.
• In BMD, the mutations result in shorter dystrophin forms that are partially functional, leading to a less severe disease manifestation.

Adeno-Associated Virus (AAV) as a Gene Therapy Vector

• AAV was initially discovered in a preparation of simian adenovirus and was later found in human tissues.
• The potential of AAV as a gene therapy vector has been explored, with the virus’s basic biology being driven by scientific curiosity.